147 related articles for article (PubMed ID: 12710205)
21. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
[TBL] [Abstract][Full Text] [Related]
22. Farnesyltransferase inhibitors: targeting the molecular basis of cancer.
Oliff A
Biochim Biophys Acta; 1999 May; 1423(3):C19-30. PubMed ID: 10382537
[No Abstract] [Full Text] [Related]
23. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
Glynn MW; Glover TW
Hum Mol Genet; 2005 Oct; 14(20):2959-69. PubMed ID: 16126733
[TBL] [Abstract][Full Text] [Related]
24. Arglabin-DMA, a plant derived sesquiterpene, inhibits farnesyltransferase.
Shaikenov TE; Adekenov SM; Williams RM; Prashad N; Baker FL; Madden TL; Newman R
Oncol Rep; 2001; 8(1):173-9. PubMed ID: 11115593
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors.
Lombardo LJ; Camuso A; Clark J; Fager K; Gullo-Brown J; Hunt JT; Inigo I; Kan D; Koplowitz B; Lee F; McGlinchey K; Qian L; Ricca C; Rovnyak G; Traeger S; Tokarski J; Williams DK; Wu LI; Zhao Y; Manne V; Bhide RS
Bioorg Med Chem Lett; 2005 Apr; 15(7):1895-9. PubMed ID: 15780629
[TBL] [Abstract][Full Text] [Related]
26. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
Cohen SJ; Ho L; Ranganathan S; Abbruzzese JL; Alpaugh RK; Beard M; Lewis NL; McLaughlin S; Rogatko A; Perez-Ruixo JJ; Thistle AM; Verhaeghe T; Wang H; Weiner LM; Wright JJ; Hudes GR; Meropol NJ
J Clin Oncol; 2003 Apr; 21(7):1301-6. PubMed ID: 12663718
[TBL] [Abstract][Full Text] [Related]
27. Assays for cyclin-dependent kinase inhibitors.
Senderowicz AM; Lahusen T
Methods Mol Med; 2003; 85():39-48. PubMed ID: 12710195
[No Abstract] [Full Text] [Related]
28. Biomarkers of anticancer activity of R115777 (Tipifarnib, Zarnestra) in human breast cancer models in vitro.
Izbicka E; Campos D; Carrizales G; Patnaik A
Anticancer Res; 2005; 25(5):3215-23. PubMed ID: 16101130
[TBL] [Abstract][Full Text] [Related]
29. The effect of the farnesyl protein transferase inhibitor SCH66336 on isoprenylation and signalling by the prostacyclin receptor.
O'Meara SJ; Kinsella BT
Biochem J; 2005 Feb; 386(Pt 1):177-89. PubMed ID: 15469414
[TBL] [Abstract][Full Text] [Related]
30. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.
Graaf MR; Richel DJ; van Noorden CJ; Guchelaar HJ
Cancer Treat Rev; 2004 Nov; 30(7):609-41. PubMed ID: 15531395
[TBL] [Abstract][Full Text] [Related]
31. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets.
Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
Nat Rev Drug Discov; 2007 Jul; 6(7):541-55. PubMed ID: 17585331
[TBL] [Abstract][Full Text] [Related]
32. Non-thiol farnesyltransferase inhibitors: N-(4-tolylacetylamino-3-benzoylphenyl)-3-arylfurylacrylic acid amides.
Mitsch A; Wissner P; Silber K; Haebel P; Sattler I; Klebe G; Schlitzer M
Bioorg Med Chem; 2004 Sep; 12(17):4585-600. PubMed ID: 15358286
[TBL] [Abstract][Full Text] [Related]
33. Farnesyl transferase inhibitors.
Li T; Sparano JA
Cancer Invest; 2008 Aug; 26(7):653-61. PubMed ID: 18665473
[No Abstract] [Full Text] [Related]
34. Farnesyltransferase inhibitors.
Kurzrock R
Clin Adv Hematol Oncol; 2005 Mar; 3(3):161-2. PubMed ID: 16166986
[No Abstract] [Full Text] [Related]
35. Geranylgeranyl diphosphate synthase: an emerging therapeutic target.
Wiemer AJ; Wiemer DF; Hohl RJ
Clin Pharmacol Ther; 2011 Dec; 90(6):804-12. PubMed ID: 22048229
[TBL] [Abstract][Full Text] [Related]
36. Broad-based quantitative structure-activity relationship modeling of potency and selectivity of farnesyltransferase inhibitors using a Bayesian regularized neural network.
Polley MJ; Winkler DA; Burden FR
J Med Chem; 2004 Dec; 47(25):6230-8. PubMed ID: 15566293
[TBL] [Abstract][Full Text] [Related]
37. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo.
Coxon FP; Ebetino FH; Mules EH; Seabra MC; McKenna CE; Rogers MJ
Bone; 2005 Sep; 37(3):349-58. PubMed ID: 16006204
[TBL] [Abstract][Full Text] [Related]
38. [Inhibitors of farnesyltransferase: a new approach for development of potential cancer drugs].
Schlitzer M
Pharm Unserer Zeit; 1998 Nov; 27(6):278-88. PubMed ID: 9894422
[No Abstract] [Full Text] [Related]
39. Perspectives on farnesyl transferase inhibitors in cancer therapy.
Mazieres J; Pradines A; Favre G
Cancer Lett; 2004 Apr; 206(2):159-67. PubMed ID: 15013521
[TBL] [Abstract][Full Text] [Related]
40. Medicine. Mouse study suggests cancer drugs could help prematurely aging kids.
Travis J
Science; 2006 Feb; 311(5763):934-5. PubMed ID: 16484462
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]